Osteoporosis is a common disorder among postmenopausal women which results in an increased risk of fractures. While several therapies improve bone strength and reduce the risk of spine and hip fracture, there is no cure for ...
Oct 11, 2017
0
45
Denosumab is a monoclonal antibody which acts as a potent anti-resorptive agent and is now widely used in the treatment of osteoporosis.
Aug 2, 2017
0
2
Postmenopausal women with osteoporosis who take denosumab long-term have increased bone density, sustained low rate of fractures, and a favorable benefit/risk profile, a new multinational study finds. The results were presented ...
Jun 23, 2014
0
1
A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic ...
Nov 28, 2013
0
0
(HealthDay)—Xgeva (denosumab) has been approved by the U.S. Food and Drug Administration to treat giant cell tumor of the bone (GCTB), a rare tumor that's most often non-cancerous.
Jun 13, 2013
0
0
(HealthDay)—Denosumab does not appear to delay fracture healing or contribute to other complications when used to treat postmenopausal women with osteoporosis, according to research published in the Dec. 5 issue of The ...
Dec 19, 2012
0
0
